公开(公告)号：US20230304097A1

公开(公告)日：2023-09-28

申请号：US18006745

申请日：2021-08-27

申请人： Fredrik JOHANSSON SWARTLING

发明人： Fredrik JOHANSSON SWARTLING ,  Sonja HUTTER

IPC分类号： C12Q1/6886 ,  A61K48/00 ,  A61K38/45 ,  A61K31/522 ,  A61P35/00

CPC分类号： C12Q1/6886 ,  A61K31/522 ,  A61K38/45 ,  A61K48/0041 ,  A61K48/0066 ,  A61P35/00 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158

摘要： A likelihood of cancer relapse is estimated for a subject by introducing ex vivo a nucleic acid molecule comprising a reporter gene under transcriptional control of a SOX9p or of a promoter operatively linked to an enhancer element comprising at least one SOX9 binding site into cancer cells obtained from a tumor sample from a subject. The cancer cells are exposed ex vivo to a cancer treatment and the amount of SOX9+ cancer cells following cancer treatment is determined based on expression of the reporter gene. The likelihood of cancer relapse following cancer treatment for the subject is estimated based on the determined amount of SOX9+ cancer cells. A combination of a viral vector comprising a suicidal gene under transcription control of a SOX9p or of a promoter operatively linked to an enhancer element comprising at least one SOX9 binding site and a prodrug can be used in treatment of a subject suffering from a cancer disease.